Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) | PAR 23 239

Opportunity Information: Apply for PAR 23 239

The Social Disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) funding opportunity (PAR-23-239) is a National Institutes of Health (NIH) discretionary grant program designed to support early-stage, exploratory research on how social disconnection contributes to suicidal thoughts and behaviors among older adults. It focuses on two related but distinct aspects of social disconnection: objective social isolation (for example, small social networks, infrequent contact, or limited participation in community life) and perceived social isolation, commonly described as loneliness. The overall goal is to deepen understanding of why and how these factors elevate suicide risk in late life and to translate that understanding into practical prevention strategies.

A central priority of this initiative is research that clarifies the mechanisms linking isolation and loneliness to suicide risk in older populations. NIH is emphasizing both neurobiological and environmental pathways. On the neurobiological side, applicants may investigate processes such as stress physiology, inflammation, neural circuitry involved in threat detection or reward processing, sleep and circadian disruption, cognitive control and decision-making changes, or other brain-body mechanisms that could plausibly connect social disconnection to despair, perceived burdensomeness, or reduced resilience. On the environmental side, projects might examine contributors like bereavement, retirement-related role loss, caregiving strain, disability, chronic pain, mobility limitations, housing instability, transportation barriers, community resource gaps, stigma, and other contextual factors that can compound disconnection and intensify vulnerability. Competitive applications will typically make a clear case for how the proposed mechanism(s) help explain the pathway from social disconnection to suicidal ideation or behavior in late life, and how measuring those mechanisms could inform prevention.

Another major emphasis is the use of an experimental therapeutics approach. In practice, this means projects should aim not just to test whether an intervention "works," but to identify, engage, and measure specific targets that are hypothesized to reduce suicide risk. The intention is to fund studies that can pinpoint actionable targets related to social connection and then develop, refine, or test interventions that directly influence those targets. The opportunity is labeled "Clinical Trial Optional," which signals that applicants may propose either clinical trial or non-trial research designs, depending on what best fits the aims. This flexibility allows for mechanistic studies, target validation, and early intervention development, as well as pilot testing of promising strategies, as long as the project remains aligned with the R21 exploratory/developmental scope.

The notice also encourages work on service delivery models that can realistically increase social connection for older adults in ways that reduce suicide risk. This can include creating new models or modifying existing systems in health care, behavioral health, aging services, community-based organizations, faith-based settings, or public health programs. Examples of relevant directions might include improved screening and referral pathways for loneliness and isolation, integration of social connection supports into primary care or geriatric services, community health worker or peer support models, technology-facilitated connection approaches that account for older adult accessibility needs, or coordinated care models that link clinical risk identification with community resources. Importantly, the service delivery focus is not simply about increasing social activity; it is about enhancing meaningful connection and belonging in a way that can plausibly prevent suicidal thoughts and behaviors.

From an administrative standpoint, this is a grant mechanism under the NIH R21 program, which generally supports exploratory, high-impact ideas and early proof-of-concept work rather than large definitive trials. The posted award ceiling is $275,000. The original closing date listed for the opportunity is 2026-09-07, reflecting a multi-year window during which applications may be accepted according to the funding announcement schedule. The program is categorized under health (CFDA 93.242), and it is offered as a discretionary grant rather than a formula or entitlement program.

Eligibility is broad and includes many types of U.S.-based organizations and certain non-U.S. entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; Indian/Native American tribal governments other than federally recognized entities; and non-domestic (non-U.S.) entities, meaning foreign organizations may apply when appropriate to the research aims.

Taken together, this opportunity is aimed at advancing late-life suicide prevention by treating social disconnection as a serious, measurable, and modifiable risk factor. It supports projects that move beyond describing associations and instead explain mechanisms, identify intervention targets, and test practical strategies or service models capable of strengthening social connection and reducing suicide risk among older adults.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
• This funding opportunity was created on 2023-07-19.
• Applicants must submit their applications by 2026-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $275,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 23 239

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: